Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

on behalf of the Heart Failure Long-Term Registry Investigators

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science